Yes, weed is a drug. By any scientific or legal definition, cannabis (marijuana) qualifies as a drug because it contains chemicals that alter how your brain and body function. The primary active compound, THC, binds directly to receptors in your brain, producing changes in mood, perception, appetite, and pain signaling. That mechanism of action is what makes any substance a drug, whether it comes from a plant, a lab, or a pharmacy.
What Makes Something a Drug
A drug is any substance that changes how your body works when you consume it. Cannabis fits this definition clearly. The plant contains over 500 distinct chemical compounds, including 125 identified cannabinoids and 120 terpenes. THC, the compound responsible for the “high,” locks onto specific receptors in your brain (called CB1 receptors) and triggers a chain of chemical signals that suppress certain cell activity while activating others. This is the same basic process by which prescription medications, alcohol, caffeine, and nicotine all work: a chemical enters your body and changes its normal functioning.
CBD, the other widely known cannabinoid, works differently. It has low attraction to those same brain receptors and doesn’t produce a high, but it still interacts with multiple receptor systems throughout the body. That biological activity is why CBD products carry dosing information and are regulated in many markets.
How the U.S. Government Classifies It
Under federal law, marijuana is currently a Schedule I controlled substance, the most restrictive category under the Controlled Substances Act of 1970. Schedule I means the government considers a substance to have a high potential for abuse and no currently accepted medical use. Heroin and LSD are also in this category.
That classification is actively changing. In 2023, the Department of Health and Human Services recommended moving marijuana to Schedule III, a category for drugs with moderate-to-low potential for dependence (where testosterone and certain pain medications sit). The FDA and the National Institute on Drug Abuse both supported this recommendation. In May 2024, the Department of Justice proposed a formal rule to reschedule marijuana to Schedule III, which received nearly 43,000 public comments. A December 2025 executive order directed the Attorney General to complete that rescheduling process as quickly as federal law allows.
Moving from Schedule I to Schedule III would not make marijuana legal for recreational use, but it would formally acknowledge its medical applications and ease restrictions on research.
FDA-Approved Medications From Cannabis
Four FDA-approved medications are derived from or chemically related to cannabis, which reinforces that the plant’s compounds function as drugs in the pharmacological sense. Epidiolex is a purified CBD product approved for certain severe seizure disorders. Three synthetic versions of THC are also approved: dronabinol in capsule form, dronabinol in liquid form, and nabilone. These are prescribed for nausea during chemotherapy and appetite loss in certain conditions.
Each of these went through the same rigorous clinical trial process as any other pharmaceutical. The fact that cannabis-derived compounds can be isolated, dosed, and prescribed like conventional medications makes the “is it a drug?” question fairly straightforward from a medical standpoint.
How It Compares to Other Drugs in Risk
Calling weed a drug doesn’t tell you much about how dangerous it is. Not all drugs carry the same risks, and cannabis sits at a notably different spot on the spectrum than many other controlled substances.
A 2022 study examining deaths in England over more than two decades (1998 to 2020) found that cannabis toxicity alone was attributed as the cause of death in exactly one case. In the vast majority of cannabis-related deaths (96%), other drugs were also involved, most commonly opioids and alcohol. The researchers concluded that the risk of death from cannabis toxicity alone is “negligible.” For comparison, opioids and alcohol are each responsible for tens of thousands of single-substance deaths annually in the U.S.
This doesn’t mean cannabis is without risk. It means the acute danger of a fatal overdose is extremely low compared to alcohol, opioids, or many prescription medications.
Cannabis Can Cause Dependence
One of the defining features of a drug is its potential to create dependence, and cannabis does carry that risk. The DSM-5, the standard diagnostic manual used in psychiatry, recognizes cannabis use disorder as a clinical condition. It’s diagnosed when someone experiences at least two of the following within a 12-month period:
- Using more cannabis, or using it longer, than intended
- Wanting to cut back but being unable to
- Spending excessive time obtaining, using, or recovering from cannabis
- Experiencing cravings
- Neglecting responsibilities at work, school, or home due to use
- Continuing use despite relationship problems it causes
- Giving up important activities to use cannabis
- Using in physically risky situations
- Continuing despite knowing it’s worsening a physical or mental health problem
- Needing more to get the same effect (tolerance)
- Experiencing withdrawal symptoms when stopping
Withdrawal symptoms from cannabis are real but generally milder than those from alcohol, opioids, or benzodiazepines. They typically include irritability, sleep problems, decreased appetite, and restlessness, usually peaking within the first week after stopping and resolving within two to three weeks.
Where International Bodies Stand
The World Health Organization’s Expert Committee on Drug Dependence has reviewed cannabis and made several recommendations that reflect its complicated status. The committee recommended keeping THC under international drug controls but also recommended that CBD specifically should not be subject to international control. This distinction recognizes that different compounds within the same plant have very different drug profiles: THC is psychoactive and carries dependence potential, while CBD does not produce intoxication and lacks abuse liability.
In practical terms, the global consensus treats cannabis as a drug that warrants regulation, while acknowledging that its risk profile and medical potential don’t align with the most restrictive classifications it was originally given decades ago. The trend across both U.S. federal policy and international health bodies is toward recognizing cannabis as a drug with legitimate medical uses and a lower risk profile than its legal classification has historically suggested.